Hi

We've got great news to report as we progress MB22001 through clinical trials. MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed specifically for take-home self administered microdosing.

We're targeting Major Depressive Disorder and related conditions with this novel medicine and testing it in the real world through our world first government approved take-home clinical trials. A patient can take MB22001 in microdoses at home and then get on with their day - its exactly what we have been testing and it is becoming a revolutionary approach to the potential scalable and affordable use of psychedelics in medical practice.

The interim data from this Phase 2a trial is in and a short explainer can be watched here . We are overwhelmed with the results. Over half the patients entering the trial with Major Depressive Disorder are in complete remission at 8 weeks, with the trial meeting its targeting endpoint with an impressive mean drop in Montgomery Asberg Depression Rating Scale (MADRS) score of 14.1 points.

Watch Video

We are thrilled at the scale of improvements in depressive symptoms and tolerability of MB22001 as we progress the drug in advanced clinical trials.

You can click the following link to see a brief presentation of the interim results.

https://youtu.be/DIB1YifPMwg

Comprehensive data will be presented in a series of papers and published in peer reviewed journals in due course.

We thank all our staff for their terrific work on these trials and our investors, advisors and friends for your relentless support.

Stay Well and stay tuned for exciting upcoming announcements!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true